AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...
AstraZeneca Pharma and Sun Pharma have announced an exclusive partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands, aiming to expand patient access across India ...
Not taking enough vitamin D can cause more harm than you’ve heard. Take the risk to heart health, for example. But no worries ...
AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...
AstraZeneca Pharma India and Sun Pharma partner to help patients living with hyperkalaemia in India: Our Bureau, Bengaluru Monday, November 17, 2025, 17:20 Hrs [IST] AstraZeneca P ...
Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the ...
AstraZeneca Pharma India shares may be in focus after the company announced a second brand partnership with Sun Pharma to ...
The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.
The report further notes that structural abnormalities in the GBM, as seen in Alport syndrome, may predispose patients to ...
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous ...
Candesartan doses in excess of the recommended antihypertensive maxima have been reported to lead to greater reductions of proteinuria than the advised doses. High-dose angiotensin-converting-enzyme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback